



Proteomics International

LABORATORIES LTD

ASX release
18 November 2025

ASX code: PIQ

Proteomics International to present at the Bell Potter Healthcare Conference 2025

Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to attendees of the Bell Potter Healthcare Conference, a virtual event being held 18-20 November 2025.

Proteomics International will present on Thursday, 20 November at 1pm (AEDT).

Authorised by Dr Richard Lipscombe (Managing Director) and Dr James Williams (Non-Executive Chairman) on behalf of the Board of PIQ.

ENDS

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of precision diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel
Investor Relations & Corporate Advisory
Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com



Proteomics International

LABORATORIES LTD

Bell Potter Healthcare Conference

Investor Presentation: Commercial Launch

18-20 November 2025

Dr. Richard Lipscombe
Managing Director

Forward Looking Statements

This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ).

You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in deciding whether or not to seek to purchase the shares of the Company. This is not an offer to subscribe for securities in the Company.

The Presentation may contain quantitative statements of anticipated future performance such as projections, forecasts, calculations, forward-looking statements or estimates all of which are based on certain assumptions (Forward Looking Statements). The Forward Looking Statements may involve subjective judgements and are based on a large number of assumptions and are subject to significant uncertainties and contingencies, many of which are outside the control of the Company and may not prove to be correct.

No representation or warranty is made that any Forward Looking Statements will be achieved, or occur, or that the assumptions upon which they are based are reasonable or the calculations from which they have been derived are correct. Actual future events may vary significantly from the Forward Looking Statements. Each Recipient should undertake their own independent review of the Forward Looking Statements, including the assumptions on which they are based and the financial calculations from which they are derived.

Material Business Risks. The Company has identified specific risks that could impact upon its future prospects. These risks are listed in the PIQ 2025 Annual Report.

Proteomics International Key Highlights



**Launching four first-in-class
diagnostics in 2025**

PromarkerD PromarkerEso
PromarkerEndo **OxiDx**



**Large addressable markets
with significant unmet
medical needs**



**Tests validated in large
clinical studies**

**Significant advantages over
current
Standards-of-Care**



Consumer driven strategy

- Targeting Primary Care & GP Clinics
- Patient digital platform built
- Proven demand with KOLs on board



Products developed

Patented

Highly attractive margins



**Funded to execute
launch strategies**

**Strategically positioned to
secure Licencing
Agreements**

Problem & Solution: a suite of novel diagnostic tests

Targeting major diseases which are currently detected late → existing outcomes are poor for patients & cost healthcare system billions of dollars

Promarker_D

Diabetic Kidney Disease

COMMERCIALISATION

- A novel and accurate blood test for predicting the onset of chronic kidney disease in type 2 and type 1 diabetes (DKD)
- Currently 1 in 2 people with diabetes will develop DKD
- DKD leads to dialysis/kidney transplant; US reimbursement price pending
- Ramp-up phase following launch in Australia and USA in Q2 and Q3 CY25

Promarker_{Endo}

Endometriosis

DEVELOPMENT

COMMERCIALISATION

- First-in-class blood test identifies all stages of endometriosis with high accuracy
- Current diagnosis takes average 7 yrs and requires invasive laparoscopy
- Launch in Australia in CY25 pending; USA to follow

Promarker_{Eso}

Esophageal Cancer

COMMERCIALISATION

- A novel and accurate blood test to diagnose esophageal cancer
- Commonly caused by chronic acid reflux (or 'GERD')
- Current diagnosis requires endoscopy + biopsy
- Ramp-up phase following launch in Australia in Q3 CY25; USA pending

OxiDx

Oxidative Stress

DEVELOPMENT

COMMERCIALISATION

- Unique test precisely identifies muscle damage & assesses training recovery
- In professional sports muscle damage accounts for 55% of injuries, while 85% of racehorses get injured during their 2- & 3- year-old racing seasons
- Launch in Australia in CY25 pending; USA to follow

Market Launch: Ramp Up → Partnering

Drive near-term revenue with maximum optionality for strategic partnering

Focus on market awareness and launch of tests



Demonstrate market adoption and sales



Grow sales via strategic partnerships

- ✓ Developed suite of highly accurate, tests for large unmet medical needs
- ✓ Platform, analytical infrastructure & digital sales pathway built
- ✓ Enables tech transfers of each clinical test to future partners
- ✓ Provides fastest pathway to achieving product launch and revenues
- ✓ Reimbursement pricing (USA) imminent for PromarkerD – other tests to follow

- ✓ Engagement with GP clinics, KOLs & end users to refine sales practices
- ✓ Grow market awareness via traditional and digital avenues
- Increase market up-take as market awareness improves
- ✓ Attractive pre-built platform for any potential licensing partner:
 - Global virtual health and diagnostic companies
- Leverage more attractive terms for out-licensing as tests are in market

- Industry and Governments are focusing on Personalised/Precision medicine
- Healthcare and diagnostic companies actively seeking new diagnostic tests
- Ongoing dialogue with prospective strategic partners
- Company will retain optionality for its tests:
 - Drive revenue through the platform
 - Non-exclusive licensing agreements & retain use of platform
 - Provide exclusive rights to licensing partners

Milestones: multiple value drivers achieved & ahead

Milestone	TARGET QTR	FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Impact
Commercial							
Australian clinical lab established		✓					Basis for all Promarker tests to be run clinically
US reference lab established		✓					Key to first US sales and reimbursement
PromarkerD launched in W. Australia		✓					Pilot launch to optimise logistics & digital framework
PromarkerD launched across Australia			✓				Enable clinical testing in Australia and tech transfer overseas
PromarkerD launched in USA		✓					Initiate pathway to significant revenues
PromarkerEso launched in Aus/USA			✓				Initiate pathway to significant revenues
PromarkerEndo launched in Aus/USA							Initiate pathway to significant revenues
Material sales of PromarkerD							Drive future revenue
Promarker tests licensing deals							Drive regional uptake and future revenue
Clinical/Technical							
Promarker tests validation studies		✓					New first-in-class diagnostic tests
Promarker diagnostics pipeline updates							New diagnostic tests in development
Reimbursement							
PromarkerD reimbursement code granted		✓					Support US roll-out
PromarkerD PLA code pricing set							Broaden usage of test in USA
PromarkerEso PLA code application							Support US roll-out


Investment Summary



Proteomics International

LABORATORIES LTD

- Commercialising x4 first-in-class blood tests for major diseases and conditions with significant unmet need
- Ramp-up phase for PromarkerD & PromarkerEso with first sales already achieved
- Commercial platform developed to drive awareness for each test in Australia and USA to attract strategic partners
- Proprietary platform technology provides engine to develop further tests
- Funding, team, infrastructure and certifications in place
- Catalyst rich Financial Year 2026



ASX:PIQ

Contact

Proteomics International

LABORATORIES LTD

Dr Richard Lipscombe

Managing Director

T: +61 8 9389 1992

E: enquiries@proteomicsinternational.com

www.proteomicsinternational.com